Market Intelligence, Clinical Progress, and High-Purity Reagents for Anticancer, Antimicrobial, and Antiparasitic Development.
"Comprehensive reagent toolkit for DHFR drug discovery. Select your modality below:"
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | Human DHFR Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence verified. HEK293 expressed. Active in enzymatic assays. Theoretical MW ~21.5 kDa. |
View DHFR Products |
| Antigen (Mutant) | DHFR Mutant Proteins (MTX-Resistant Variants L22F, F31S, F34S; DHFR Deficiency Variants rs387906619, rs121913223) Theoretical MW confirmed, sequence verified. For resistance mechanism and selectivity studies. |
View DHFR Products |
| Species Orthologs | P. falciparum / E. coli DHFR Proteins For antimalarial/antibacterial selectivity screening. Endotoxin controlled, mass spec identity confirmed. |
View DHFR Products |
| Gene Delivery | DHFR Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target validation. |
View DHFR Products |
| Benchmark Binder | Anti-DHFR Detection Antibody Recombinant rabbit monoclonal for Western blot, ELISA, and IP validation. |
View DHFR Products |
| Validator | DHFR siRNA Set For knockdown verification and specificity control in cell-based assays. |
View DHFR Products |
| Related Target: TYMS | TYMS (Thymidylate Synthase) Downstream folate pathway enzyme; synergistic combination target for polypharmacology. |
View TYMS Products |
| Related Target: SHMT1 | SHMT1 (Serine Hydroxymethyltransferase 1) Mitochondrial one-carbon metabolism node; metabolic bypass resistance mechanism. |
View SHMT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Resistance Mutation Screening (Oncology/Infectious Disease) | Pre-validated mutant proteins (L22F, F31S, F34S, DHFR deficiency variants) with >95% purity and sequence verification |
| Species Selectivity (Human vs Pathogen) | Ortholog panel: Human, P. falciparum, E. coli DHFR with strict mass spec identity confirmation |
| High-Throughput Enzymatic Assays | Low endotoxin (<1 EU/µg) ensures consistent Michaelis-Menten kinetics |
| False Positive Elimination | Validated siRNA and isotype control antibodies included for specificity confirmation |
Live DHFR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The DHFR inhibitor landscape is bifurcated between mature antifolate chemotherapies (methotrexate, pemetrexed, pralatrexate) and next-generation selective inhibitors targeting resistant variants. While generic competition dominates the rheumatoid arthritis and oncology markets, the critical unmet need lies in overcoming acquired resistance mutations (L22F, F31S, F34S in human DHFR; S108N, I164L in P. falciparum) and developing species-selective inhibitors for malaria and antibacterial applications. As structural biology advances, rational design of mutant-selective DHFR inhibitors represents the primary growth vector, requiring high-quality wild-type and mutant recombinant proteins for preclinical validation. In parallel, the emergence of PROTAC degraders and bifunctional modalities offers a new avenue to target resistant cancers by directly degrading DHFR protein rather than simply inhibiting its enzymatic activity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Antifolate) | Eli Lilly (Alimta), Spectrum (Folotyn), Generic MTX | NSCLC, T-cell Lymphoma, RA | Resistance Mutant Enzymatic Assay (Need purified WT and mutant DHFR) |
| PROTAC / Degrader | Academic / Biotech pipelines | Refractory Cancers, Resistant Cancers | Target engagement & degradation assays (Need benchmark antibodies & WT/mutant DHFR) |
| Antiparasitic Antifolate | GSK, Medicines for Malaria Venture | Malaria (P. falciparum), Toxoplasmosis | Species Selectivity Panel (Human vs Parasite DHFR orthologs) |
| Antibacterial | Various generics and biotechs | UTI, Respiratory infections | Bacterial vs Human DHFR Selectivity Screen |
| Combination Therapy | Novartis, Pfizer | Methotrexate-resistant cancers | DHFR + TYMS Dual Target Biochemical Assay |